TQC3302 / Sino Biopharm - LARVOL DELTA

TQC3302-I-01: A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=33 | Terminated | Sponsor: Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. | N=57 ➔ 33 | Trial completion date: Dec 2026 ➔ Aug 2026 | Recruiting ➔ Terminated; This study shall be terminated as a result of strategic adjustments to the company-sponsored research and development of TQC3302 Inhalation Spray.

Enrollment change • Trial completion date • Trial termination • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=44 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.

New P1 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases